
    
      Phase II Multicentre, Randomised, Double-Blind, Placebo and Active-Controlled, Dose-Ranging,
      Parallel Group Study of the Safety and Efficacy of The Oral Neurokinin-1 Receptor Antagonist,
      GW679769 in Combination with Ondansetron Hydrochloride and Dexamethasone for the Prevention
      of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Highly Emetogenic
      Cisplatin-based Chemotherapy.
    
  